PE20081043A1 - Composicion farmaceutica que comprende bifosfonatos - Google Patents

Composicion farmaceutica que comprende bifosfonatos

Info

Publication number
PE20081043A1
PE20081043A1 PE2007001337A PE2007001337A PE20081043A1 PE 20081043 A1 PE20081043 A1 PE 20081043A1 PE 2007001337 A PE2007001337 A PE 2007001337A PE 2007001337 A PE2007001337 A PE 2007001337A PE 20081043 A1 PE20081043 A1 PE 20081043A1
Authority
PE
Peru
Prior art keywords
biphosphonate
pharmaceutical composition
formulation
composition including
polymeric matrix
Prior art date
Application number
PE2007001337A
Other languages
English (en)
Inventor
Rolf Loeffler
Holger Petersen
Juergen Sigg
Gesine Winzenburg
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38740337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081043(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20081043A1 publication Critical patent/PE20081043A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UNA FORMULACION QUE COMPRENDE MICROPARTICULAS QUE CONTIENEN UNA SAL DE CALCIO, MAGNESIO O ZINC, DE BAJA SOLUBILIDAD, DE UN BIFOSFONATO DE FORMULA (I), DONDE X ES H, OH, AMINO, ENTRE OTROS; R ES H O ALQUILO C1-C4; Rx ES UNA CADENA LATERAL QUE COMPRENDE UN GRUPO AMINO O UN HETEROCICLO QUE CONTIENE NITROGENO; DONDE DICHO BIFOSFONATO SE ENCUENTRA DENTRO DE UNA MATRIZ POLIMERICA. EL BIFOSFONATO DE FREFERENCIA ES EL ACIDO 2-(IMIDAZOL-1-IL)-1-HIDROXI-ETAN-1,1-DIFOSFONICO Y LA MATRIZ POLIMERICA COMPRENDE UN POLI-LACTIDO-CO-GLICOLIDO LINEAL O RAMIFICADO. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION. DICHA FORMULACION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS INCLUYENDO CANCER
PE2007001337A 2006-10-05 2007-10-03 Composicion farmaceutica que comprende bifosfonatos PE20081043A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82826106P 2006-10-05 2006-10-05

Publications (1)

Publication Number Publication Date
PE20081043A1 true PE20081043A1 (es) 2008-09-17

Family

ID=38740337

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001337A PE20081043A1 (es) 2006-10-05 2007-10-03 Composicion farmaceutica que comprende bifosfonatos

Country Status (7)

Country Link
US (1) US20100047306A1 (es)
AR (1) AR063121A1 (es)
AU (1) AU2007304205A1 (es)
CL (1) CL2007002865A1 (es)
PE (1) PE20081043A1 (es)
TW (1) TW200824695A (es)
WO (1) WO2008040763A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITPA20070034A1 (it) * 2007-10-30 2009-04-30 Tetrapharm S R L Bifosfonati geminali, loro preparazione e loro impiego in campo oncologico.
CA2701516A1 (en) 2007-11-30 2009-06-04 Novartis Ag C2-c5-alkyl-imidazole-bisphosphonates
EA201001578A1 (ru) * 2008-04-04 2011-06-30 Новартис Аг Фармацевтическая композиция с бисфосфонатом
EA201100964A1 (ru) * 2008-12-23 2012-02-28 Новартис Аг Фенилалкилимидазолбисфосфонаты
US20100247607A1 (en) * 2009-03-26 2010-09-30 Psivida Us, Inc. Implantable formulations of bisphosphonic acids
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
JP5852569B2 (ja) 2009-07-31 2016-02-03 タール ファーマシューティカルズ，インコーポレイテッド 結晶化方法および生物学的利用能
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
PT2525815E (pt) * 2010-01-24 2015-03-05 Novartis Ag Micropartículas de polímero biodegradável irradiadas
AR075721A1 (es) * 2010-03-05 2011-04-20 Eriochem Sa Composicion farmaceutica que comprende una solucion de acido zoledronico.
AU2011239935A1 (en) 2010-04-16 2012-11-08 Novartis Ag Methods and compositions for improving implant osseointegration
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
US20170319749A1 (en) * 2014-11-14 2017-11-09 Nanyang Technological University Bioresorbable-magnesium composite
WO2016190407A1 (ja) 2015-05-27 2016-12-01 東レ株式会社 抗血栓性材料
CN105582850B (zh) * 2015-12-22 2017-08-29 陕西科技大学 一种线性‑超支化磷酸酯盐表面活性剂及其制备方法
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
EP3954386A4 (en) * 2019-04-11 2022-07-06 Xiamen Innovax Biotech Co., Ltd. PREPARATION OF A ZINC ZOLEDRONATE MICRO-NANOPARTICLE ADJUVANT AND ITS USE AS A VACCINE ADJUVANT
WO2023172387A1 (en) * 2022-03-08 2023-09-14 Celanese Eva Performance Polymers Llc Implantable medical device for the delivery of aromatase inhibitor
CN117618322A (zh) * 2022-08-15 2024-03-01 深圳善康医药科技股份有限公司 一种长效缓控释植入剂的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4244423A1 (de) * 1992-12-29 1994-06-30 Boehringer Mannheim Gmbh Wasserlösliche Calciumsalze der 1-Hydroxy-3-(methylpentylamino)propan-1,1-bisphosphonsäure, ihre Herstellung und Verwendung als Arzneimittel
DE4244422A1 (de) * 1992-12-29 1994-06-30 Boehringer Mannheim Gmbh Schwerlösliche Zink- und Magnesiumsalze von 1,1-Bisphosphonsäuren, ihre Herstellung und Verwendung als Arzneimittel
WO1996039107A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
BR0310087A (pt) * 2002-05-17 2005-08-16 Wyeth Corp Veìculos sólidos injetáveis para ácido hialurÈnico para aplicação de proteìnas osteogênicas
KR100648515B1 (ko) * 2004-05-04 2006-11-27 (주)아모레퍼시픽 비스포스포네이트-함유 고분자 미립구를 포함하는 골-관련질환 치료 또는 예방용 서방 효과를 갖는 주사제

Also Published As

Publication number Publication date
AR063121A1 (es) 2008-12-30
US20100047306A1 (en) 2010-02-25
AU2007304205A1 (en) 2008-04-10
WO2008040763A1 (en) 2008-04-10
CL2007002865A1 (es) 2008-05-23
TW200824695A (en) 2008-06-16

Similar Documents

Publication Publication Date Title
PE20081043A1 (es) Composicion farmaceutica que comprende bifosfonatos
TR201907575T4 (tr) Hayvan parazitlerini kontrol etmeye yönelik faydalı ajanlar olarak aminobenzamid türevleri.
MY145721A (en) Non-irritating compositions containing zinc salts
NZ602685A (en) Concentrated protein formulations and uses thereof
EA201100873A1 (ru) Пиридилоксииндолы - ингибиторы vegf-r2 и их применение для лечения заболевания
MA32903B1 (fr) Inhibiteurs de proteine-kinases
PE20091960A1 (es) Compuestos de insulina lispro pegilada
PA8622401A1 (es) Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico,procesos para su preparacion y su uso como medicamentos
UY30649A1 (es) Compuestos de biaril éter urea
BR112012023139A2 (pt) composição farmacêutica para a prevenção ou o tratamento de doença do fígado gordo não alcóolico e o método para a prevenção ou tratamento de doença do fígado gordo não alcóolico usando a mesma.
PE20141539A1 (es) Una nueva composicion terapeutica que contiene apomorfina como principio activo
ES2720954T3 (es) Formulaciones estabilizadas de estatina
BR112013000776A2 (pt) método e formulação para tratamento de deficiência de ácido siálico
DK1885187T3 (da) Fremgangsmåde til behandling af lægemiddelresistent cancer
PE20220751A1 (es) Composiciones solidas que comprenden un agonista del glp-1, un inhibidor del sglt2 y una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico
NZ593524A (en) A nonapeptide with anti-tumour activity
BR112013019513A2 (pt) métodos para o tratamento de úlceras diabéticas do pé
CR9857A (es) Composiciones de suplemento de hierro con tolerancia mejorada
MA30554B1 (fr) Malates et formes polymorphes de l'acide ( 3s,5s)-7-[3-amino-5-methyl-piperidinyl ]-1-cyclopropyl-1,4-dihydro-8- methoxy-4-oxo-3-quinoleine-carboxylique
MX339096B (es) Compuestos inhibidores de metaloproteasa a base de feniletiniltiofeno y su uso en el tratamiento del dolor y otras enfermedades.
BRPI0713743C1 (pt) composto, e, composição farmacêutica
BR112015002041A2 (pt) formulação transdérmica contendo inibidores de cox
AR067048A1 (es) Formulaciones acuosas de acetaminofen para inyeccion.
EA201390345A1 (ru) Терапевтическое болеутоляющее средство
AR075567A1 (es) Composicion antimicrobiana.

Legal Events

Date Code Title Description
FD Application declared void or lapsed